Long-acting amylin analogues for the management of obesity.

Mathiesen, David S et al.·Current opinion in endocrinology·2022·
RPEP-063612022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Cagrilintide has shown promising weight loss effects in early-stage trials.

Key Numbers

How They Did This

The study summarizes findings from preclinical and early-stage clinical trials of long-acting amylin analogues.

Why This Research Matters

These treatments could offer new options for obesity management, addressing a significant public health issue. Understanding their long-term effects is crucial for their successful implementation.

What This Study Doesn't Tell Us

The study primarily reviews early-stage research, and long-term effects in diverse populations remain unclear.

Trust & Context

Original Title:
Long-acting amylin analogues for the management of obesity.
Published In:
Current opinion in endocrinology, diabetes, and obesity, 29(2), 183-190 (2022)
Database ID:
RPEP-06361

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-06361·https://rethinkpeptides.com/research/RPEP-06361

APA

Mathiesen, David S; Bagger, Jonatan I; Knop, Filip K. (2022). Long-acting amylin analogues for the management of obesity.. Current opinion in endocrinology, diabetes, and obesity, 29(2), 183-190. https://doi.org/10.1097/MED.0000000000000716

MLA

Mathiesen, David S, et al. "Long-acting amylin analogues for the management of obesity.." Current opinion in endocrinology, 2022. https://doi.org/10.1097/MED.0000000000000716

RethinkPeptides

RethinkPeptides Research Database. "Long-acting amylin analogues for the management of obesity." RPEP-06361. Retrieved from https://rethinkpeptides.com/research/mathiesen-2022-longacting-amylin-analogues-for

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.